Anti-cancer property from a Thai medicinal plant Second title: Oxyresveratrol: Anti-cancer breast cancer and the mechanism of actions

Sarayut Radapong (SR)*, Satyajit D. Sarker, and Kenneth J. Ritchie (KJR)*

* corresponding authors SR: S.Radapong@2017.ljmu.ac.uk KJR: K.J.Ritchie@ljmu.ac.uk

DOI: 10.5281/zenodo.4383349

Keywords

Oxyresveratrol, Artocarpus lakoocha, Anticancer, mechanism, microarray

Received: 21 March 2020 Accepted: 30 May 2020 Published: 31 December 2020

"Oxyresveratrol poses potent cytotoxicity to several kinds of cancer cells. The compound moderated various molecular alterations of breast cancer cells including apoptosis, cell proliferation, metastasis and cancer pathways. repair Interestingly, Oxyresveratrol down-regulates RAD51 in homologous and genes recombination, which breaks the mechanism of self-repair resulting in overcoming the drug resistance."

Background

Breast cancer is a major cause of cancer-related deaths. It is estimated that over 9.6 million deaths from cancer in 2018 (WHO 2020, n.p.). Anti-cancer drugs are normally used in all stages of cancer development, but the failure treatment may occur from chemoresistance (Shender *et al* 2018, 473). Oxyresveratrol (OXY) is a naturally occurring polyphenol belonging to the group of the stilbenoids, which is richest in *Artocarpus lakoocha*'s heartwood, an indigenous plant in Thailand (Mongolsuk *et al* 1957, 2231). OXY has been shown to possess various potent bioactivities with the main property being an antioxidant, anti-inflammatory, tyrosinase inhibition, anti-virus and anti-cancer (Chatsumpun *et al* 2016, 488; Rahman *et al* 2017, 23). In consideration of its chemical structure, which is similar to the well-known antioxidant, resveratrol, this compound may share the anti-cancer property. The previous report found this compound posed cytotoxicity to human hormone-dependent breast cancer (T47D), human cervical adenocarcinoma (HeLa), human non-small-cell lung carcinoma (A549) (Chatsumpun *et al* 2016, 488). The evidence of the anticarcinogenic activity of OXY has been reported. However, the precise mechanism involved in the modulation of carcinogenesis remains to be elucidated.

Method

The cytotoxicity of OXY was evaluated on several cancerous and non-cancerous cells using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assays. Microarray Human Clariom S arrays (a 400 format array) (Affymetrix Inc., Santa Clara, California, USA), following the manufacturer's recommendations, was then implemented to elucidate the genes and biological

61

AJ TRE pathways altered in MCF-7, human breast cancer cells treated with two different OXY concentrations (50 μ M and 100 μ M) for 24 h. Quantitative polymerase chain reaction and western blot analysis were then used to confirm the gene expression.

Result

OXY displayed dose- and time-dependent cytotoxicity on human breast cancer cells (MCF-7) and then the cells were subsequently exposed to OXY. By using Transcriptome Analysis Console (TAC) Software (Thermo Fisher Scientific, California, USA), A total of 686 genes were found to have altered mRNA expression levels of two-fold or more in the 50 µM OXY-treated group (262 upregulated and 424 downregulated genes). Total 2,338 genes were found to be differentially expressed in the 100 µMtreated group (907 upregulated and 1,431 downregulated genes). Interestingly, OXY was found to moderate the genes mainly in apoptosis or programmed cell death by activating the key genes both extrinsic and intrinsic pathways via dead receptors (FAS, TNFR1 and APOL2/TRAIL) and mitochondrial apoptotic genes (BAX, BAK, DIABLO and APAF1), respectively through caspase cascade. Cyclindependent kinases(CDKs) are the main enzymes playing the crucial role in cell proliferation including CDK2, CDK4 and cyclin proteins, which were also suppressed by OXY resulting in blocking DNA synthesis in G1 and S phases and the cell cycle was subsequently arrested. OXY also inhibited the expression of CXCR4 and its ligand (CXCL12) causing anti-cell spreading or metastasis. Most importantly, OXY inhibited the genes in the cancer DNA repair pathway; the most affected were RAD51 and genes in homologous recombination, which can break the mechanism of self-repair resulting in overcoming the drug resistance.



Oxyresveratrol (OXY) posed cytotoxicity to MCF-7, breast cancer cells by moderating the genes mainly on apoptosis or programmed cell death by activating the key genes both extrinsic and intrinsic pathways via dead receptors (FAS, TNFR1 and APOL2/TRAIL) and mitochondrial apoptotic genes (BAX, BAK, DIABLO and APAF1), respectively through the caspase cascade. Cyclin-dependent kinases(CDKs) are the main enzymes playing the crucial role in cell proliferation including CDK2, CDK4 and cyclin proteins, which were also suppressed by OXY resulting in blocking DNA synthesis in G1 and S phase and the cell cycle was subsequently arrested. OXY also inhibited the expression of CXCR4 and its ligand (CXCL12) causing anti-cell spreading or metastasis. Most importantly, OXY inhibited the genes in the cancer DNA repair pathway; the most affected were RAD51 and genes in homologous recombination.

Discussion and conclusion

OXY moderated genes in the key pathways of cancer hallmarks including apoptosis, cell proliferation, metastasis and cancer repair pathways. Downregulation of RAD51 and some genes in homologous recombination may be the key role of self-repair causing cancer resistance (Leon-Galicia *et al* 2018, 3025). OXY has the potential to be a promising anticancer drug or help overcome chemotherapeutics resistance.

About the authors

Sarayut is a doctoral student in Prof Satyajit D. Sarker and Dr Kenneth J. Ritchie's phytochemicals laboratory at Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK.

Acknowledgements

The authors acknowledge the support from The Royal Thai government, Thailand (Project number: R253184) and the excellent support from Liverpool John Moores University for the laboratory facilities.

References

WHO. 2020. n.d. Breast cancer. Accessed 5 30, 2020. http://

www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/

- Chatsumpun, Nutputsorn, Taksina Chuanasa, Boonchoo Sritularak, Vimolmas Lipipun, Vichien Jongbunprasert, Somsak Ruchirawat, Poonsakdi Ploypradith, and Kittisak Likhitwitayawuid.
 2016. "Oxyresveratrol: Structural Modification and Evaluation of Biological Activities." *Molecules* 21(4): 488-489.
- Leon-Galicia, I., J. Diaz-Chavez, M. E. Albino-Sanchez, E. Garcia-Villa, R. Bermudez-Cruz, J. Garcia-Mena, L. A. Herrera, A. Garcia-Carranca, and P. Gariglio. 2018. "Resveratrol Decreases Rad51 Expression and Sensitizes Cisplatin-Resistant Mcf-7 Breast Cancer Cells." *Oncol. Rep* 39(6): 3025-3033.
- Mongolsuk, S., Alexander Robertson, and R. Towers. 1957. "2,3',4,5'-Tetrahydroxystilbene from Artocarpus Lakoocha." *J. Chem. Soc* : 2231-2233.
- Rahman, Md Ataur, Kausik Bishayee, Ali Sadra, and Sung-Oh Huh. 2017. "Oxyresveratrol Activates Parallel Apoptotic and Autophagic Cell Death Pathways in Neuroblastoma Cells." *Biochim. Biophys. Acta, Gen. Subj* 1861(2): 23-36.
- Shender, V. O., G. P. Arapidi, M. S. Pavlyukov, P. V. Shnaider, K. S. Anufrieva, G. A. Stepanov, and V. M. Govorun. 2018. "The Role of Intercellular Communication in Cancer Progression." *Russ. J. Bioorg. Chem* 44(5): 473-80.

000

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, which permits to copy and redistribute the material in any medium or format. You are also allowed to remix, transform, and build upon the material under the following terms: 1) You must give appropriate credit, provide a link to the license, and indicate if changes were made. 2) You may not use the material for commercial purposes. 3) If you remix, transform or build upon the material, you must distribute your contributions under the same license as the original. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/

63

Academic Journal for Thai Researchers in Europe 31 December 2020/ Volume 1/ Issue 1 www.ajtre.org This journal is publicly available and can be accessed without any charge.



EDITORIAL

Editor-in-chief: Kridsadakorn Chaichoompu Chief journal editor: Issara Orikasa Managing editors: Tanut Ungwattanapanit, Sittichoke Som-am, Piyapat Saranrittichai, Nad Siroros

PUBLISHING

Management: Kridsadakorn Chaichoompu Journal: Issara Orikasa Website: Teerat Pitakrat, Piyapat Saranrittichai

MANAGEMENT

Chief supervisor: Manop Sittidech Supervisor: Thanakorn Chanmalee, Jaturong Amonchaisup Administration: Siriluk Pumirat, Puracheth Rithchumpon, Sirasak Tepjit Event: Puracheth Rithchumpon, Arada Jamnongpipatkul, Sittichoke Som-am, Nad Siroros, Piyapat Saranrittichai, Kanthanakorn Noysena, Sirasak Tepjit, Kridsadakorn Chaichoompu Public Relations: Jompoj Wongphechauxsorn, Nad Siroros, Arada Jamnongpipatkul, Puracheth Rithchumpon, Atiruj Jerddeesakul Graphic: Atiruj Jerddeesakul, Issara Orikasa

MANAGEMENT OFFICE

Office of Science and Technology, Royal Thai Embassy, Brussels, Belgium. Tel: +32 (02) 675 0797 E-mail: info@thaiscience.eu

Academic Journal for Thai Researchers in Europe (ISSN: 2730-2784) published annually by the Office of Science and Technology, Royal Thai Embassy, Brussels, Belgium.

The journal was registered as an online journal at the National Library of Thailand, Thanon Samsen, Wachira Phayaban, Dusit District, Bangkok 10300, Thailand. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form without prior permission from the Office of Science and Technology, Royal Thai Embassy, Brussels, Belgium (info@thaiscience.eu).

©2020 Office of Science and Technology, Royal Thai Embassy, Brussels, Belgium. All rights reserved.